Gosse Bote Bruinsma

FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada.

viDA Therapeutics, Inc. operates as a biotechnology company. It offers discovery, development and commercialization of novel and targeted therapeutics for the treatment of inflammatory and age related diseases. The firm's discovery platform is based on novel research regarding a distinctly different and recently identified, extracellular role for granzymes in the destruction and inflammation of tissues. The company was founded by Alistair Duncan Jr. and David Granville in 2008 and is headquartered in Vancouver, Canada.

Vivendy Therapeutics Ltd. develops enzyme replacement therapy and biological products. It has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity-enhancing the efficacy of the therapy in MPS IVA significantl. The company was founded in March 2006 and is headquartered in Basel, Switzerland.

Curidium Medica Ltd. engaged in the development targeted medicines and companion diagnostics used in the medical sector. The company was founded on July 25, 2003 and was headquartered in Wetherby, the United Kingdom.

Axonyx, Inc. is an biopharmaceutical company, which manufactures medical products and technologies to treat Alzheimer's disease and other Central Nervous System disorders. It is located in New York, NY.

Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands.

Part of Marvell Technology, Inc., ClinTrials Research, Inc. engages in clinical research organization. The company is based in Cary, NC. ClinTrials Research was acquired by Indigo Acquisition Corp on April 03, 2001 for $110.42 million.

Zambon Co. SpA operates as an industrial holding company with interests in pharmaceuticals and chemicals. The company was founded by Gaetano Zambon on November 11, 1906 and is headquartered in Bresso, Italy.

IDEA AG develops pain therapeutics and biopharmaceutical drugs. The firm develops and commercializes non-invasive therapeutic drugs and the targeted pain therapeutics for arthritic and osteoporosis-related inflammation, chronic pain and diseases. Its technology platform is based on proprietary carriers applied on skin and engineered to diminish side effects and increase drug potency. The company founded by Gregor Cevc in 1993 and is headquartered in Munich, Germany.